“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Lupin launches Moxifloxacin Ophthalmic Solution USP 0.5%
Mumbai, Baltimore, February 14, 2020: Pharma major Lupin Limited (Lupin) announced the launch of Moxifloxacin Ophthalmic Solution USP, 0.5%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin’s Pithampur (Unit-II) facility, India.
Moxifloxacin Ophthalmic Solution USP, 0.5% is the AT2-rated generic equivalent of Moxeza® of Novartis. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms.
Moxifloxacin Ophthalmic Solution USP, 0.5% (RLD: Moxeza®) had an annual sales of approximately USD 10 million in the U.S. (IQVIA MAT December 2019).
About Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.
Lupin has 15 manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on Twitter: https://twitter.com/LupinGlobal | LinkedIn: https://www.linkedin.com/company/lupinglobal/ | Facebook: http://www.facebook.com/LupinWorld/
For further information or queries please contact -
Head – Investor Relations and Corporate Communications
Tel: +91-22 6640 8237
General Manager – Corporate Communications
Tel: +91-22-6640 2532
*Safe Harbor Statement
Moxeza® is a registered trademark of Novartis AG Corporation Switzerland (Novartis Group Company)